Across TCGA pan-cancer cohorts, HACD2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HACD2 data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher HACD2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated HACD2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where HACD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	0.850	0.517	.001	44	view →
LUAD	DFS	Median	All	0.885	1.000	.009	4	view →
LSCC	DFS	Median	All	0.831	0.495	.036	3	view →
CCRCC	OS	Median	All	0.741	1.000	.027	2	view →
GBM	OS	Median	All	0.840	0.866	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: HACD2 tumor-vs-normal RNA expression · all HACD2 data types